Des-gamma-carboxy Prothrombin
Also known as: DCP
Use
The des-gamma-carboxy prothrombin (DCP) assay is intended as a risk assessment for the development of hepatocellular carcinoma in patients with chronic liver diseases. Elevated DCP values have been shown to be associated with an increased risk for developing hepatocellular carcinoma. Patients with elevated serum DCP should be more intensely evaluated for evidence of hepatocellular carcinoma. This assay aids in the surveillance and monitoring of hepatocellular carcinoma.
Special Instructions
The uTASWako method is used. Results obtained with different assay methods or kits cannot be used interchangeably. Medication containing vitamin K preparations may cause a negative bias of the DCP values. Medication containing vitamin K antagonist or antibiotic may cause a positive bias of the DCP values.
Limitations
Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease. The assay is not a standalone test and should be interpreted in conjunction with other clinical findings.
FDA ApprovedNew York Approved
Methodology
Other
Biomarkers
LOINC Codes
- 34444-0
Result Turnaround Time
1-5 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.5 mL
Container
ARUP Standard Transport Tube
Collection Instructions
Allow specimen to clot completely at room temperature. Separate from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube.
Causes for Rejection
Plasma
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 8 hours |
| Refrigerated | 1 week |
| Frozen | 3 weeks (avoid repeated freeze/thaw cycles) |